Pilot study on beliefs about radiotherapy in cancer patients  by Sanz Cortés, A. et al.
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S362–S368 S365
Pain incidence in our radiotherapy oncology unit
M. Martínez Agra1, A. Carregal Ran˜ó2, P. Willisch Santamaría1, L. López Louzara1, M. Caeiro Mun˜oz1,
V. Ochagavia Galilea1, V. Mun˜oz Garzón1
1 Hospital Do Meixoeiro, Servicio de Oncología Radioterápica, Spain
2 Hospital Do Meixoeiro, Servicio de Anestesia y Reanimación, Spain
Introduction. Pain is a frequent symptom in oncology, approximately 50% of cancer patients have pain at some moment in their
disease, and increase by 75–90% in advanced stages. Pain may be associated with the tumor, with treatment or be related with
other causes. Presents an important physical,mental and social impact, so it is important to give anadequate analgesic treatment.
Objective. To analyze the pain incidence, intensity and treatment in our Radiotherapy Oncology unit.
Materials and methods. An observational study has been realized interviewing 200 patients of our unit. We have made them several
questions about pain: presence/absence, cause, location, days with pain, intensity according to VAS and treatment.
Results. Of the 200 patients, 120 were men and 80 were women, with a mean age of 64 years (26–87). 147 patients were asymp-
tomatic (73.5%) and 53 had pain (26.5%), pain was related to the disease and/or the treatment to 79.2% of cases and independent
to 20.8%. Of the 53 patients with pain, 69.8% were taking medication (ﬁrst step: 45.9%, second step: 10.9% and third step: 43.2%).
We analyzed VAS maximum, middle and minimum by steps of analgesic: ﬁrst step (6.4/4/1.6), second step (6/4.2/2.2), and third
step (6.6/2.3/2.3).
Conclusion. Most of our patients have no pain. Those who are symptomatic are mainly palliative or head and neck tumours. They
have an average of days a week with pain of 6 (1–7) and a mode of 7. Analyzing the patients by steps, we observe that in the
ﬁrst and second, only one patient in each group is well treated, others have a maximum VAS above 4; would be necessary to
step up. Third step patients also show a high maximum average VAS, could be to have low doses, absence of rescue analgesia or
adjuvant, or they need a fourth step using invasive techniques.
http://dx.doi.org/10.1016/j.rpor.2013.03.587
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Introduction. Tapentadol is a centrally acting analgesic with a dual mechanism of action ( receptor agonism and inhibiting the
reuptake of norepinephrine).
Objective. To evaluate the efﬁcacy of Tapentadol in cancer patients with chronic and/or acute pain.
Patients and methods. Between October 2011–September 2012, 28 patients were treated with Tapentadol in 3 Departments. Retro-
spective descriptive analysis of treatment with Tapentadol (SPSS 20.0).
Results. Patients were 10 women (35.7%) and 18 men (64.3%). Age range 28–85 years (mean=60.8). The 17.8% of patients stopped
treatment because of death, 7.1% because of improvement and 3.6% because of pruritus. The 71.4% continued treatment. The
14.3% increased dose to achieve analgesia. (a) Primary tumor type: The most common cancer were 21.4% lungs, 21.4% head
and neck, 17.8% breast. (b) Pain was due to: 32.1% tumour, 28.6% bone metastases, 14.3% benign problems, 10.7% induced by
RT, 7.1% visceral metastases and 7.1% neuropathic pain. (c) VAS before and after treatment: the mean VAS pretreatment=7.2
and posttreatment=3 (4.2 points difference). The 71.4% of patients progressed to mild pain (VAS=<4). (d) Tapentadol mean
dose=114. 3mg. The dose most used was 50mg (42.9%). (e) Other medications associated: none (17.8%), rapid onset fentanyl
(60.7%), antiepileptics (28.6%), steroids (28.6%) NSAIDs (21.4%), morphine (7.1%), anxiolytics (7.1%), antidepressants (3.6%), 5%
lidocaine (3.6%) and acupuncture (3.6%) f) Analgesic efﬁcacy: 100% of cases. Mean analgesic = 41.7% and maximum=87.5%. (g)
Side effects: well tolerated with mild effects (pruritus, constipation) in 3 cases (10.7%).
Conclusions. Our data support the use of Tapentadol pain in cancer patients with moderate to severe chronic or acute pain (VAS>
5). Tapentadol is an effective pain reliever with few side effects.
http://dx.doi.org/10.1016/j.rpor.2013.03.588
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Introduction. Radiotherapy (RT) is the modality of cancer treatments to which less attention has been paid with respect to psy-
chological problems. Thus, there may be signiﬁcant psychopathological symptoms and an emotional response due to lack of
information or that is inappropriate (Die Trill, 2003; Cruzado and Olivares, 2005).
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Objectives. This study aims to assess the beliefs and fears of patients about this technique before its application. Besides it
analyzes the clinical symptoms of anxiety and depression associated.
Methods. Prospective and longitudinal study, with two measurement times (before RT application and after). Was performed in
Group IMO Foundation with a sample of 50 patients with various oncology diseases, undergoing conventional radiotherapy. The
assessment procedure was: (a) ad hoc questionnaire beliefs about radiotherapy; (b) anxiety and clinical depression questionnaire,
and (c) satisfaction with the information received scale. Analysis: It will be a descriptive analysis of the characteristics of the
population-level sociodemographic, clinical and satisfaction with the information. It will apply a correlation analysis between
symptoms of anxiety and depression and beliefs about RT. On the other hand, it will use a nonparametric test (Wilcoxon) to
determine the change in beliefs about RT and anxiety-depression.
Conclusions. Adequate information on cancer treatments reduces uncertainty, promotes treatment compliance and minimizes
stress (Cruzado, 2010). It is therefore important not only explain the medical procedure but also the reason for using the same
and the effects produced (Cruzado and Olivares, 2005).
http://dx.doi.org/10.1016/j.rpor.2013.03.589
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Introduction. There has been growing evidence during the last decade on the beneﬁts of physical exercise as an intervention to
control cancer related side effects such as cancer related fatigue (CRF) and pain. Nordic Walking (NW) is a physical activity with
great physiological and psychosocial advantages over more traditional aerobic types of exercise such as walking or running. It
consists on adding a pair of speciﬁc poles, that help propel the body forward, to the normal walking pattern. In this way the work
of the upper and lower body is integrated in a symmetric and balanced way.
Objectives. To determine the potential beneﬁts from NW as a physical exercise indicated for patients undergoing radiotherapy.
Methodology Literature review.
Results. NW signiﬁcantly increases oxygen consumption, heart rate and energy expenditure when compared to normal walking at
the same speed, however, and due to the effort being spread between the upper and lower body, the perceived exertion remains
low. NW can therefore result in signiﬁcant physiological beneﬁts without increased perceived exertion. This is particularly
relevant when considering adherence to exercise programs.
Conclusions. NW as an intervention to improve the physical ﬁtness of patients undergoing radiotherapy can potentially result
in better physiological outcomes when compared to other forms of aerobic exercise. Moreover, it is related to lower perceived
exertion which can palliate the poor adherence to exercise programs. There is a need for randomized controlled trials using NW
as an intervention in order to produce evidence and inform future practice.
http://dx.doi.org/10.1016/j.rpor.2013.03.590
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Introduction. Women with breast cancer might develop psychological distress including anxiety and depression during diagnosis
and treatment and after treatment. Most women’s lives change as well as their perspectives on and appreciation of life.
Objectives. The purpose of this study was to examine the experiences of breast cancer patients during adjuvant radiotherapy.
Materials and methods. Women with radiotherapy breast cancer at the Hospital “Puerta del Mar”, Cadiz, in October 2012 were
included in the study. We asked them to provide written informed consent. We used a psychosocial impact test developed by the
Department of Medical Oncology at the University Hospital Marques de Valdecilla, Santander. Answers evaluation: depression
and anxiety test >5 needs psychological support. Twenty-ﬁve patient consented to participate in the study. They answered the
questionnaires in privacy and they could choose the questions they wanted to answer. Patients age was 53.91 years (36–81). Level
of education: primary: 44%, secondary: 32%. Coping with the disease and treatment: Acceptance: 28% (7/25). Active coping: 28%.
Resignation: 28%. Principal carer: Partner 40% (8/25), family 40%.
Results. Trait depression, score from 0/10: 0: 44%, < 5: 72% (18/25); ≥5: 28% (7/25). Trait Anxiety: 0: 32%; <5: 84%; ≥5: 16%. Ques-
tionnaires: Have you felt pain?: No/low: 84%. Have you felt nauseated?: No: 96%. Were you tired?: No: 64%. Have you had trouble
sleeping?: No: 64%. Do you feel nervous? No: 72%. Were you worried?: No: 84%. Did you feel irritable?: No: 84%. Does it affect your
family life?: No: 80. Does it affect your sex life?: No: 60%. Pretty/a lot: 20%, NS/NC: 20%.
